Acuity Polymers Receives FDA Clearance for Expanded Indications of Acuity 200 and Acuity 100
Acuity Polymers has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded indications of its Acuity 200 (fluoroxyfocon A) and Acuity 100 (hexafocon A) daily wear GP contact lenses. The newly granted FDA clearance includes the option of treating the contact lenses with polyethylene glycol.
According to the company, specialty eyecare practitioners can now prescribe Acuity 200 and Acuity 100 GP contact lenses to patients who have ocular surface disease such as dry eye syndrome, graft-versus-host disease, Sjögren’s syndrome, and filamentary keratitis. Other approved indications include limbal stem cell deficiency, disorders of the skin, neurotrophic keratitis, and corneal exposure that might benefit from the presence of an expanded tear reservoir and protection against an adverse environment.
Latinos en Optometry Launches Redesigned Website and New Domain Name
Latinos en Optometry, a nonprofit association dedicated to increasing representation of Latinos and Spanish-speaking professionals within the optometry and larger eyecare professional community,announced the launch of its redesigned website and new domain name, www.latinosenoptometry.org.
The newly designed site features information and resources for prospective and current optometry students, including a series of archived and upcoming free webinars, supported by Transitions Optical, in which Latinos en Optometry board members share their experiences and offer advice to support and inspire students to consider a career in optometry.
AOA President Resigns
Citing personal reasons, Ronald L. Benner, OD, has resigned as American Optometric Association (AOA) president. After being informed, the AOA board of trustees met and designated the organization’s president-elect, Steven T. Reed, OD, as acting president for the next two months. Dr. Reed’s planned installation as president remains set for June 2024 during Optometry’s Meeting in Nashville, and the one-year term will run through June 2025.
DryEye Rescue Becomes Sole U.S. Distributor for InflammaDry
DryEye Rescue announced that it has been selected as the sole distributor for InflammaDry in the U.S. InflammaDry is a rapid, in-office CLIA-waived test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients who have dry eye disease. According to the company, this innovative test allows eyecare professionals to accurately identify ocular surface disease, leading to optimal treatment pathways.
Nordic Group B.V. Announces the Launch of Lacrifill Canalicular Gel
Nordic Pharma Inc., a subsidiary of Nordic Group B.V., has launched Lacrifill Canalicular Gel, a novel therapy for dry eye in the U.S. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
According to the company, the Lacrifill Canalicular Gel is administered through a simple in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for six months.